Clinical Trials Directory

Trials / Sponsors / Fondazione Ricerca Traslazionale

Fondazione Ricerca Traslazionale

Academic / Other · 15 registered clinical trials — 5 currently recruiting.

StatusTrialPhaseStarted
RecruitingPhase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertio
Metastatic NSCLC - Non-Small Cell Lung Cancer
Phase 22025-12-02
RecruitingA Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSC
NSCLC
Phase 22025-04-17
RecruitingNeoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)
Stage III NSCLC
Phase 22025-03-27
RecruitingRandomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-c
Non-small-cell Lung Cancer Patients
Phase 22022-05-02
Active Not RecruitingEfficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell
Metastatic Non Small Cell Lung Cancer
Phase 22021-10-12
RecruitingStudy Investigating Anti-drug Antibodies in NSCLC Patients Exposed to Checkpoint Inhibitors (IMB)
NSCLC
—2021-05-20
UnknownBest EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations
NSCLC
Phase 22020-06-12
Active Not RecruitingAtezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)
Non-small-cell Lung Cancer Patients
Phase 22020-03-02
UnknownCrizotinib in ALK Rearranged Non-small-cell Lung Cancer
Non Small Cell Lung Cancer, Advanced Cancer, Metastatic Cancer
—2019-05-16
UnknownCABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation
Non-Small Cell Lung Cancer
Phase 22018-09-21
UnknownAn Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Plati
Squamous-Cell Lung Cancer
Phase 22017-09-13
UnknownPF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Phase 22017-06-13
UnknownPrognostic Value of PD-L1 in NSCLC
Carcinoma, Non-Small-Cell Lung
—2017-03-03
UnknownThe Predictive Role of Programmed Death Ligand 1 (PD-L1) and Neutrophil to Lymphocyte Ratio (NLR) in Non-Small
To Define an Easy and Feasible Panel Which May be Routinely Applied to Select Patients for Immunotherapy Avoiding More Complex and Expensive Methods
—2015-02-15
UnknownCrizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (M
Carcinoma, Non-Small-Cell Lung
Phase 22014-12-01